ASH 2015 | Overview of RESONATE-2 clinical trial of ibrutinib in CLL

John Gribben and Stephan Stilgenbauer

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).

Share this video  
Similar topics
Related videos
Venetoclax-resistance conferring mutation in CLL identified
Piers Blombery
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
An exciting era for CAR T-cell therapy
Mohamad Mohty
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
Chronic Lymphocytic Leukemia
Ibrutinib
RESONATE-2
ASH 2015
Interview
4th December 2015
More from John Gribben
ASH 2014: Treating mantle cell lymphoma (Part 2)
Approaches to overcome side effects of idelalisib for follicular lymphoma
Financial benefit of combining two expensive drugs for CLL
More from Stephan Stilgenbauer
Venetoclax and bendamustine plus rituximab or obinutuzumab for CLL
What should we be focusing on in CLL research?
Venetoclax-antibody combinations to come in CLL
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals